Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age

Figures & data

Table 1 Patient demographics and average values of study parameters

n	Males	21	3
	Females		18
		Mean ± SD	Range
Age at presentation		53±18.59	22–86
Number of injections		5.71±2.79	1–12
Initial CDVA (LogMAR)		0.55±0.23	1–0.18
Final CDVA (LogMAR)		0.44±0.30	1.09–0

Abbreviation: CDVA, corrected distance visual acuity.

Figure 1 Scatter plot demonstrating the correlation between the number of injections received and the age of the patients.

Figure 2 Scatter plot demonstrating the correlation between improvement in CDVA after treatment and the age of patients.

Abbreviations: CDVA, corrected distance visual acuity; ETDRS, early treatment of diabetic retinopathy study.

Table 2 Comparison of study parameters between the younger and the older age groups

Age, years	≤40	>40	P-value
N	7	14
Number of injections	3.57±1.99, 1–6	6.79±2.55, 3–12	0.007 (Mann–Whitney U test)
Initial CDVA (LogMAR)	0.62±0.23, 0.3–1	0.52±0.23, 0.18–1	0.4 (Mann–Whitney U test)
Final CDVA (LogMAR)	0.20±0.19, 0–0.52	0.55±0.28, 0.15–1.09	0.004 (Mann–Whitney U test)
Improvement in CDVA (ETDRS letters)	20.83±15.42, 0–35	−1.55±11.08, −26–15	0.006 (Mann–Whitney U test)
Stable or improved (n, %)	7 (100%)	8 (57%)	0.04 (χ^2 test)

Notes: Data presented as mean ± SD, range. Bold data are statistically significant.

Abbreviations: CDVA, corrected distance visual acuity; ETDRS, early treatment of diabetic retinopathy study.